rafapress / Shutterstock.com

18 September 2024FeaturesUnified Patent CourtJan Phillip Rektorsche, Matthew Royle

Takeaways from landmark UPC decision: Novartis v Celltrion

A recent UPC ruling involving Novartis has major implications for determining jurisdiction, claim interpretation and imminent infringement, as Jan Phillip Rektorschek and Matthew Royle of Taylor Wessing explain.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@worldipreview.com

More on this story

Unified Patent Court

DexCom suffers second patent revocation at hands of UPC

17 September 2024 The court rejected the medical device company’s auxiliary requests and nixed patent in 17 territories although it seems receptive to these amendments in general, say Laura Orlando and Rachel Montagnon of Herbert Smith Freehills

Unified Patent Court

‘Be prepared, and don’t assume at the UPC’: Christopher Stothers

2 September 2024 A vocal advocate of greater UPC transparency, Freshfields’ Christopher Stothers shares his views on the court’s journey so far, and why it is still so exciting.

UK court sets Warner and Paramount interim licence rate payable to Nokia

Tata customers Apple and Tesla reportedly held to ransom after hack

SpaceX launches into public orbit, but what now for its secretive IP strategy?

Bigger verdicts, fewer injunctions: AI, telecoms, and trade secrets shake up litigation

Disney hit by 11-country injunction over video streaming tech

Exclusive: ‘Cultural differences are an asset’ at the UPC

Fish & Richardson brings in Samsung IP leader

Via hires tech licensing and litigation expert for strategy role

Takeaways from landmark UPC decision: Novartis v Celltrion

More on this story

Editor's picks

Editor's picks

More articles